Does the media refer more to SABS or CRDF?

In the previous week, SAB Biotherapeutics and SAB Biotherapeutics both had 2 articles in the media. Cardiff Oncology's average media sentiment score of 1.85 beat SAB Biotherapeutics' score of 0.93 indicating that Cardiff Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SAB Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor CRDF or STRO?

In the previous week, Sutro Biopharma had 3 more articles in the media than Cardiff Oncology. MarketBeat recorded 5 mentions for Sutro Biopharma and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 1.85 beat Sutro Biopharma's score of 1.15 indicating that Cardiff Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Sutro Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor UPB or CRDF?

In the previous week, Upstream Bio had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 3 mentions for Upstream Bio and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 1.85 beat Upstream Bio's score of 0.97 indicating that Cardiff Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation and earnings, CRDF or IFRX?

Cardiff Oncology has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiff Oncology $590K 159.54 -$45.85M -$0.60 N/A InflaRx $30K 10,266.78 -$51.63M -$0.58 N/A

Is CRDF or CLLS more profitable?

Cellectis has a net margin of -102.34% compared to Cardiff Oncology's net margin of -7,885.43%. Cellectis' return on equity of -94.19% beat Cardiff Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Cardiff Oncology -7,885.43% -103.10% -75.52% Cellectis -102.34% -94.19% -21.34%

Does the media prefer CRDF or CLLS?

In the previous week, Cardiff Oncology and Cardiff Oncology both had 2 articles in the media. Cardiff Oncology's average media sentiment score of 1.85 beat Cellectis' score of 0.94 indicating that Cardiff Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cardiff Oncology (CRDF) Competitors

$1.21 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.21 0.00 (0.00%)

As of 09/11/2026 07:30 PM Eastern

Compare

CRDF vs. SABS, STRO, UPB, IFRX, and CLLS

Should you buy Cardiff Oncology stock or one of its competitors? Cardiff Oncology's main competitors and comparable companies include SAB Biotherapeutics (SABS), Sutro Biopharma (STRO), Upstream Bio (UPB), InflaRx (IFRX), and Cellectis (CLLS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cardiff Oncology compare to SAB Biotherapeutics?

SAB Biotherapeutics (NASDAQ:SABS) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

SAB Biotherapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

In the previous week, SAB Biotherapeutics and SAB Biotherapeutics both had 2 articles in the media. Cardiff Oncology's average media sentiment score of 1.85 beat SAB Biotherapeutics' score of 0.93 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiff Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

SAB Biotherapeutics has higher revenue and earnings than Cardiff Oncology. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	235.06	$13.27M	-$1.30	N/A
Cardiff Oncology	$590K	159.54	-$45.85M	-$0.60	N/A

SAB Biotherapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,885.43%. SAB Biotherapeutics' return on equity of -6.74% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-6.74%	-6.06%
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%

SAB Biotherapeutics currently has a consensus target price of $12.00, indicating a potential upside of 251.91%. Cardiff Oncology has a consensus target price of $7.50, indicating a potential upside of 519.83%. Given Cardiff Oncology's higher probable upside, analysts clearly believe Cardiff Oncology is more favorable than SAB Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

7.8% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 7.4% of SAB Biotherapeutics shares are held by insiders. Comparatively, 8.8% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

SAB Biotherapeutics beats Cardiff Oncology on 8 of the 15 factors compared between the two stocks.

How does Cardiff Oncology compare to Sutro Biopharma?

Cardiff Oncology (NASDAQ:CRDF) and Sutro Biopharma (NASDAQ:STRO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are owned by institutional investors. 8.8% of Cardiff Oncology shares are owned by company insiders. Comparatively, 1.8% of Sutro Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Sutro Biopharma had 3 more articles in the media than Cardiff Oncology. MarketBeat recorded 5 mentions for Sutro Biopharma and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 1.85 beat Sutro Biopharma's score of 1.15 indicating that Cardiff Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Sutro Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardiff Oncology has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market.

Sutro Biopharma has a net margin of -395.25% compared to Cardiff Oncology's net margin of -7,885.43%. Sutro Biopharma's return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%
Sutro Biopharma	-395.25%	N/A	-88.12%

Cardiff Oncology presently has a consensus target price of $7.50, suggesting a potential upside of 519.83%. Sutro Biopharma has a consensus target price of $47.30, suggesting a potential upside of 180.55%. Given Cardiff Oncology's higher probable upside, equities research analysts plainly believe Cardiff Oncology is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Sutro Biopharma	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Cardiff Oncology has higher earnings, but lower revenue than Sutro Biopharma. Cardiff Oncology is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	159.54	-$45.85M	-$0.60	N/A
Sutro Biopharma	$102.48M	2.73	-$191.09M	-$11.97	N/A

Summary

Sutro Biopharma beats Cardiff Oncology on 10 of the 17 factors compared between the two stocks.

How does Cardiff Oncology compare to Upstream Bio?

Upstream Bio (NASDAQ:UPB) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

Upstream Bio has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

Cardiff Oncology has lower revenue, but higher earnings than Upstream Bio. Cardiff Oncology is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	110.12	-$143.44M	-$2.90	N/A
Cardiff Oncology	$590K	159.54	-$45.85M	-$0.60	N/A

In the previous week, Upstream Bio had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 3 mentions for Upstream Bio and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 1.85 beat Upstream Bio's score of 0.97 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upstream Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiff Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

16.3% of Cardiff Oncology shares are held by institutional investors. 16.5% of Upstream Bio shares are held by company insiders. Comparatively, 8.8% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Upstream Bio has a net margin of -4,955.67% compared to Cardiff Oncology's net margin of -7,885.43%. Upstream Bio's return on equity of -48.40% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,955.67%	-48.40%	-46.57%
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%

Upstream Bio currently has a consensus price target of $29.67, indicating a potential upside of 417.74%. Cardiff Oncology has a consensus price target of $7.50, indicating a potential upside of 519.83%. Given Cardiff Oncology's higher probable upside, analysts plainly believe Cardiff Oncology is more favorable than Upstream Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

Upstream Bio beats Cardiff Oncology on 9 of the 16 factors compared between the two stocks.

How does Cardiff Oncology compare to InflaRx?

Cardiff Oncology (NASDAQ:CRDF) and InflaRx (NASDAQ:IFRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

In the previous week, Cardiff Oncology had 1 more articles in the media than InflaRx. MarketBeat recorded 2 mentions for Cardiff Oncology and 1 mentions for InflaRx. InflaRx's average media sentiment score of 1.87 beat Cardiff Oncology's score of 1.85 indicating that InflaRx is being referred to more favorably in the news media.

Company	Overall Sentiment
Cardiff Oncology	Very Positive
InflaRx	Very Positive

Cardiff Oncology has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, InflaRx has a beta of 2.52, suggesting that its share price is 152% more volatile than the broader market.

InflaRx has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,885.43%. InflaRx's return on equity of -53.56% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%
InflaRx	N/A	-53.56%	-43.02%

Cardiff Oncology currently has a consensus target price of $7.50, suggesting a potential upside of 519.83%. InflaRx has a consensus target price of $7.33, suggesting a potential upside of 250.88%. Given Cardiff Oncology's higher probable upside, equities research analysts clearly believe Cardiff Oncology is more favorable than InflaRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
InflaRx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 8.8% of Cardiff Oncology shares are held by insiders. Comparatively, 16.3% of InflaRx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cardiff Oncology has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	159.54	-$45.85M	-$0.60	N/A
InflaRx	$30K	10,266.78	-$51.63M	-$0.58	N/A

Summary

InflaRx beats Cardiff Oncology on 12 of the 17 factors compared between the two stocks.

How does Cardiff Oncology compare to Cellectis?

Cardiff Oncology (NASDAQ:CRDF) and Cellectis (NASDAQ:CLLS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

Cardiff Oncology has higher earnings, but lower revenue than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	159.54	-$45.85M	-$0.60	N/A
Cellectis	$79.59M	3.91	-$67.59M	-$0.65	N/A

Cardiff Oncology has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, Cellectis has a beta of 2.92, suggesting that its stock price is 192% more volatile than the broader market.

In the previous week, Cardiff Oncology and Cardiff Oncology both had 2 articles in the media. Cardiff Oncology's average media sentiment score of 1.85 beat Cellectis' score of 0.94 indicating that Cardiff Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardiff Oncology currently has a consensus target price of $7.50, indicating a potential upside of 519.83%. Cellectis has a consensus target price of $7.00, indicating a potential upside of 125.81%. Given Cardiff Oncology's higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 8.8% of Cardiff Oncology shares are held by company insiders. Comparatively, 16.4% of Cellectis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cellectis has a net margin of -102.34% compared to Cardiff Oncology's net margin of -7,885.43%. Cellectis' return on equity of -94.19% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%
Cellectis	-102.34%	-94.19%	-21.34%

Summary

Cellectis beats Cardiff Oncology on 10 of the 16 factors compared between the two stocks.

Get Cardiff Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRDF vs. The Competition

Export

Metric	Cardiff Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$94.13M	$3.86B	$7.16B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-2.02	14.18	274.94	25.33
Price / Sales	159.54	1,378.88	633.80	90.72
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	1.81	15.12	10.33	6.21
Net Income	-$45.85M	-$22.86M	$3.50B	$358.54M
7 Day Performance	11.01%	-4.34%	-3.32%	-2.35%
1 Month Performance	22.97%	0.54%	-0.53%	-3.23%
1 Year Performance	-40.98%	40.74%	23.51%	8.79%

Cardiff Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRDF Cardiff Oncology	2.722 of 5 stars	$1.21 flat	$7.50 +519.8%	-41.0%	$94.13M	$590K	N/A	20	Positive News
SABS SAB Biotherapeutics	3.1759 of 5 stars	$3.72 flat	$12.00 +222.6%	+60.8%	$338.47M	$1.32M	N/A	140	News Coverage
STRO Sutro Biopharma	3.7166 of 5 stars	$20.07 flat	$47.30 +135.7%	+92.3%	$332.78M	$102.48M	N/A	240	Positive News
UPB Upstream Bio	2.6853 of 5 stars	$6.01 flat	$29.67 +393.6%	-67.4%	$329.17M	$2.85M	N/A	38
IFRX InflaRx	2.0867 of 5 stars	$2.22 flat	$7.33 +230.3%	+65.9%	$327.16M	$30K	N/A	60	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRDF) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardiff Oncology (CRDF) Competitors

CRDF vs. SABS, STRO, UPB, IFRX, and CLLS

How does Cardiff Oncology compare to SAB Biotherapeutics?

Summary

How does Cardiff Oncology compare to Sutro Biopharma?

Summary

How does Cardiff Oncology compare to Upstream Bio?

Summary

How does Cardiff Oncology compare to InflaRx?

Summary

How does Cardiff Oncology compare to Cellectis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF vs. The Competition

Cardiff Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardiff Oncology (CRDF) Competitors

CRDF vs. SABS, STRO, UPB, IFRX, and CLLS

How does Cardiff Oncology compare to SAB Biotherapeutics?

Which has more volatility and risk, SABS or CRDF?

Does the media refer more to SABS or CRDF?

Which has higher valuation & earnings, SABS or CRDF?

Is SABS or CRDF more profitable?

Do analysts recommend SABS or CRDF?

Do institutionals & insiders believe in SABS or CRDF?

Summary

How does Cardiff Oncology compare to Sutro Biopharma?

Do insiders and institutionals have more ownership in CRDF or STRO?

Does the media favor CRDF or STRO?

Which has more volatility & risk, CRDF or STRO?

Is CRDF or STRO more profitable?

Do analysts recommend CRDF or STRO?

Which has higher earnings & valuation, CRDF or STRO?

Summary

How does Cardiff Oncology compare to Upstream Bio?

Which has more volatility and risk, UPB or CRDF?

Which has stronger valuation and earnings, UPB or CRDF?

Does the media favor UPB or CRDF?

Do insiders & institutionals believe in UPB or CRDF?

Is UPB or CRDF more profitable?

Do analysts recommend UPB or CRDF?

Summary

How does Cardiff Oncology compare to InflaRx?

Does the media refer more to CRDF or IFRX?

Which has more risk & volatility, CRDF or IFRX?

Is CRDF or IFRX more profitable?

Do analysts rate CRDF or IFRX?

Do insiders & institutionals hold more shares of CRDF or IFRX?

Which has preferable valuation and earnings, CRDF or IFRX?

Summary

How does Cardiff Oncology compare to Cellectis?

Which has higher earnings & valuation, CRDF or CLLS?

Which has more risk & volatility, CRDF or CLLS?

Does the media prefer CRDF or CLLS?

Do analysts rate CRDF or CLLS?

Do insiders & institutionals believe in CRDF or CLLS?

Is CRDF or CLLS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF vs. The Competition

Cardiff Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools